Thioether acetamides as P3 binding elements for tetrahydropyrido-pyrazole cathepsin S inhibitors.

A series of tetrahydropyrido-pyrazole cathepsin S (CatS) inhibitors with thioether acetamide functional groups were prepared with the goal of improving upon the cellular activity of amidoethylthioethers. This Letter describes altered amide connectivity, in conjunction with changes to other binding elements, resulting in improved potency, as well as increased knowledge of the relationship between this chemotype and human CatS activity.

[1]  Mary Pat Beavers,et al.  Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S. , 2004, Journal of medicinal chemistry.

[2]  Cheryl A. Grice,et al.  Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1. , 2010, Bioorganic & medicinal chemistry letters.

[3]  J. Deussing,et al.  Proteases involved in MHC dass II antigen presentation , 1999, Immunological reviews.

[4]  A. Waterson,et al.  Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[5]  Wen Jiang,et al.  Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[6]  John J. M. Wiener,et al.  Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors. Part 2: Modification of P3, P4, and P5 regions. , 2010, Bioorganic & medicinal chemistry letters.

[7]  Cheryl A. Grice,et al.  The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[8]  G. Dranoff,et al.  Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.

[9]  Wen Jiang,et al.  Pyrazole-based cathepsin S inhibitors with improved cellular potency. , 2007, Bioorganic & medicinal chemistry letters.

[10]  J. Falgueyret,et al.  Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. , 2005, Journal of medicinal chemistry.

[11]  Lars Karlsson,et al.  Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[12]  A. Ray,et al.  Cysteine cathepsin S as an immunomodulatory target: present and future trends , 2008, Expert opinion on therapeutic targets.

[13]  A. Rudensky,et al.  The role of lysosomal proteinases in MHC class Il‐mediated antigen processing and presentation , 1999, Immunological reviews.